FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989351687> ?p ?o ?g. }

• W2989351687 endingPage "2626" @default.
• W2989351687 startingPage "2626" @default.
• W2989351687 abstract "BACKGROUND: Outcome of infants with acute lymphoblastic leukemia (ALL), especially those with rearrangement of MLL (KMT2A) gene (MLL-r), is extremely poor. A strategy to perform allogeneic hematopoietic stem cell transplantation (HSCT) for all the infants with MLL-r ALL in first remission (1CR) have been tested in the previous Japanese trials MLL96/98/03, however, the improvement was modest. Given the recent evidence of a limited role of HSCT especially in infants lacking poor prognostic factors, efficacy and safety of an intensive chemotherapy and risk stratification to limit HSCT for only infants with high-risk of relapse were evaluated in the JPLSG MLL-10 trial (UMIN000004801). PATIENTS & METHODS: Infants age less than 365 days with ALL were registered in the MLL-10 study and were stratified by their MLL gene status, age at diagnosis, and presence of CNS disease; low-risk (LR), if the patients had germline MLL gene (MLL-g); intermediate-risk (IR), if the patients with MLL-r ALL were age 180 days or older and lack CNS disease; high-risk (HR), if the patients with MLL-r ALL were age <180 days or having CNS disease. All the infants with MLL-r ALL received Interfant induction followed by COG AALL0631 post-remission chemotherapy with modification of adding high-dose cytarabine in early intensification phase. All the HR cases were allocated to HSCT in 1CR. LR cases were treated based on the Japanese MLL96/98 MLL-g chemotherapy. Minimal residual disease (MRD) was evaluated in 3 methods, flowcytometry, PCR of MLL fusion transcripts, and PCR targeting IgH/TCR rearrangements, but were not used to guide therapies. RESULTS: A total of 90 eligible infants with ALL were registered in the MLL-10 study between Jan/2011 and Dec/2014; 15 cases were stratified as LR, 19 as IR, and 56 as HR. Remission status was evaluated after 2 chemotherapy courses; 82 (91.1%) achieved 1CR, 3 failed to achieve 1CR, and 5 discontinued the trial before CR evaluation. No early death was observed. With median follow-up period of 1954 days (range, 534-2835 days) in the live patients, 3-year probability of event-free survival (pEFS) and overall survival (pOS) were 70.9% (95% CI, 60.0-79.3%) and 86.6% (77.6-92.2%), respectively. Among the MLL-r cases, 3-year pEFS and pOS were 66.2% (53.9-75.9%) and 83.9% (73.4-90.5%), respectively. According to the risk groups, 3-year pEFS were 93.3% (61.2-99.0%) for LR, 94.4% (66.6-99.2%) for IR, and 56.6% (42.4-68.6%) for HR cases. Regarding the MRD studies, correlation of MRD results in 3 methodologies seemed reasonable, but while flow-MRD could be evaluated in 85 cases, MLL-fusion PCR-MRD (MLL-r cases only) and IgH/TCR PCR-MRD could only be evaluated in 55 and 50 cases, respectively. In the univariable analysis for MLL-r cases, female sex (P=0.04), younger age at diagnosis (P=0.01), and 0.01%< flow-MRD after 2 courses of chemotherapy (P<0.01) had negative impact on pEFS. In multivariable analysis, female sex (P=0.01) and positive flow-MRD (P<0.01) were poor prognostic. Among the 38 HR cases who received HSCT in 1CR per protocol, 3-year probability of disease-free survival was 65.7% (48.3-78.4%) and only one non-relapse death was observed. CONCLUSIONS: Introduction of intensive chemotherapy enabled us to spare allogeneic HSCT in 1CR at least in a subset of infants with MLL-r ALL without compromising their outcome. This was accomplished also because of the aggressive supportive care provided to the study cases, such as full hospitalization during and after the intensive treatment phases, intensive use of rasburicase to prevent tumor lysis syndromes, and aggressive infection prophylaxis. However, outcome of HR MLL-r cases is still unsatisfactory, and introduction of novel agents is mandatory for further improvement in the outcome of infants with ALL. Figure Disclosures No relevant conflicts of interest to declare." @default.
• W2989351687 created "2019-11-22" @default.
• W2989351687 creator A5002554232 @default.
• W2989351687 creator A5007428793 @default.
• W2989351687 creator A5016286590 @default.
• W2989351687 creator A5019098042 @default.
• W2989351687 creator A5026840406 @default.
• W2989351687 creator A5028818190 @default.
• W2989351687 creator A5029932023 @default.
• W2989351687 creator A5035340824 @default.
• W2989351687 creator A5040079244 @default.
• W2989351687 creator A5040540101 @default.
• W2989351687 creator A5045834709 @default.
• W2989351687 creator A5046980140 @default.
• W2989351687 creator A5051701709 @default.
• W2989351687 creator A5055440287 @default.
• W2989351687 creator A5055776624 @default.
• W2989351687 creator A5066965561 @default.
• W2989351687 creator A5078462673 @default.
• W2989351687 creator A5080093171 @default.
• W2989351687 creator A5080763444 @default.
• W2989351687 creator A5087756926 @default.
• W2989351687 date "2019-11-13" @default.
• W2989351687 modified "2023-09-28" @default.
• W2989351687 title "Intensive Chemotherapy Along with Aggressive Supportive Care Can Spare Stem Cell Transplantation in a Subset of Patients without Compromising an Outcome in Infants with Acute Lymphoblastic Leukemia; A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL-10" @default.
• W2989351687 doi "https://doi.org/10.1182/blood-2019-121328" @default.
• W2989351687 hasPublicationYear "2019" @default.
• W2989351687 type Work @default.
• W2989351687 sameAs 2989351687 @default.
• W2989351687 citedByCount "0" @default.
• W2989351687 crossrefType "journal-article" @default.
• W2989351687 hasAuthorship W2989351687A5002554232 @default.
• W2989351687 hasAuthorship W2989351687A5007428793 @default.
• W2989351687 hasAuthorship W2989351687A5016286590 @default.
• W2989351687 hasAuthorship W2989351687A5019098042 @default.
• W2989351687 hasAuthorship W2989351687A5026840406 @default.
• W2989351687 hasAuthorship W2989351687A5028818190 @default.
• W2989351687 hasAuthorship W2989351687A5029932023 @default.
• W2989351687 hasAuthorship W2989351687A5035340824 @default.
• W2989351687 hasAuthorship W2989351687A5040079244 @default.
• W2989351687 hasAuthorship W2989351687A5040540101 @default.
• W2989351687 hasAuthorship W2989351687A5045834709 @default.
• W2989351687 hasAuthorship W2989351687A5046980140 @default.
• W2989351687 hasAuthorship W2989351687A5051701709 @default.
• W2989351687 hasAuthorship W2989351687A5055440287 @default.
• W2989351687 hasAuthorship W2989351687A5055776624 @default.
• W2989351687 hasAuthorship W2989351687A5066965561 @default.
• W2989351687 hasAuthorship W2989351687A5078462673 @default.
• W2989351687 hasAuthorship W2989351687A5080093171 @default.
• W2989351687 hasAuthorship W2989351687A5080763444 @default.
• W2989351687 hasAuthorship W2989351687A5087756926 @default.
• W2989351687 hasBestOaLocation W29893516871 @default.
• W2989351687 hasConcept C126322002 @default.
• W2989351687 hasConcept C143998085 @default.
• W2989351687 hasConcept C187212893 @default.
• W2989351687 hasConcept C2776694085 @default.
• W2989351687 hasConcept C2777408962 @default.
• W2989351687 hasConcept C2778041864 @default.
• W2989351687 hasConcept C2778336483 @default.
• W2989351687 hasConcept C2778461978 @default.
• W2989351687 hasConcept C2779823535 @default.
• W2989351687 hasConcept C2781107101 @default.
• W2989351687 hasConcept C2909962599 @default.
• W2989351687 hasConcept C2911091166 @default.
• W2989351687 hasConcept C71924100 @default.
• W2989351687 hasConceptScore W2989351687C126322002 @default.
• W2989351687 hasConceptScore W2989351687C143998085 @default.
• W2989351687 hasConceptScore W2989351687C187212893 @default.
• W2989351687 hasConceptScore W2989351687C2776694085 @default.
• W2989351687 hasConceptScore W2989351687C2777408962 @default.
• W2989351687 hasConceptScore W2989351687C2778041864 @default.
• W2989351687 hasConceptScore W2989351687C2778336483 @default.
• W2989351687 hasConceptScore W2989351687C2778461978 @default.
• W2989351687 hasConceptScore W2989351687C2779823535 @default.
• W2989351687 hasConceptScore W2989351687C2781107101 @default.
• W2989351687 hasConceptScore W2989351687C2909962599 @default.
• W2989351687 hasConceptScore W2989351687C2911091166 @default.
• W2989351687 hasConceptScore W2989351687C71924100 @default.
• W2989351687 hasIssue "Supplement_1" @default.
• W2989351687 hasLocation W29893516871 @default.
• W2989351687 hasOpenAccess W2989351687 @default.
• W2989351687 hasPrimaryLocation W29893516871 @default.
• W2989351687 hasRelatedWork W2108413184 @default.
• W2989351687 hasRelatedWork W2138205116 @default.
• W2989351687 hasRelatedWork W2161996216 @default.
• W2989351687 hasRelatedWork W2623663692 @default.
• W2989351687 hasRelatedWork W2737199857 @default.
• W2989351687 hasRelatedWork W2784634394 @default.
• W2989351687 hasRelatedWork W2950740625 @default.
• W2989351687 hasRelatedWork W2989351687 @default.
• W2989351687 hasRelatedWork W2998600066 @default.
• W2989351687 hasRelatedWork W373319614 @default.
• W2989351687 hasVolume "134" @default.
• W2989351687 isParatext "false" @default.
• W2989351687 isRetracted "false" @default.
• W2989351687 magId "2989351687" @default.
• W2989351687 workType "article" @default.